{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:56:03Z","timestamp":1781549763863,"version":"3.54.5"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1757","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved the oral substance P\/neurokinin-1 (NK-1) receptor antagonist tradipitant (Nereus \u2013 Vanda) for prevention of vomiting induced by motion in adults. Tradipitant is the first drug to be approved for motion sickness in more than 40 years. Other oral substance P\/NK-1 receptor antagonists (i.e., aprepitant, rolapitant, and netupitant) have been available for years for prevention of chemotherapy-induced nausea and vomiting.<\/jats:p>","DOI":"10.58347\/tml.2026.1757a","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:06:57Z","timestamp":1781546817000},"page":"97-98","source":"Crossref","is-referenced-by-count":0,"title":["Tradipitant (Nereus) for Motion Sickness"],"prefix":"10.58347","volume":"68","member":"37151","published-online":{"date-parts":[[2026,6,22]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:06:57Z","timestamp":1781546817000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1757a"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":0,"journal-issue":{"issue":"1757","published-online":{"date-parts":[[2026,6,22]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2026.1757a","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}